Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Shire plc, the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE CII with the proton pump inhibitor Prilosec OTC 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of Prilosec OTC with ADDERALL XR resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters of active medication were not altered for either VYVANSE or ADDERALL XR when coadministered with Prilosec OTC.


Today in Pharmacokinetics...keeping you current

Pediatric antifungal agents
Current Opinion in Infectious Diseases, 10/28/09

Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing Haemodialysis: An Open-Label, Single-Centre Study
Clinical Drug Investigation, 10/15/09

Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options
Current Drug Targets, 10/23/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address